SWOG 0919 AML

SWOG 0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)

Type of Study
Cancer (Oncology) - Leukemia
Location
Swedish Cancer Institute
Short Description

Purpose: This phase II trial is studying how well giving idarubicin and cytarabine together with pravastatin works in treating patients with poor-risk acute myeloid leukemia.

Status
Open to Enrollment
Principal Investigator
Gary Goodman, M.D.
Eligibility Notes
  • Must have previously morphologically confirmed diagnosis of acute myeloid leukemia (AML)
  • No acute promyelocytic leukemia (i.e., APL, FAB M3) or blastic transformation of chronic myelogenous leukemia
  • Patients with relapsed/refractory AML must meet all of the following:
    • must have at least 1 prior induction chemotherapy for AML
    • disease must be documented by a bone marrow examination
    • must not have received chemotherapy within 14 days prior to registration
    • must not have received autologous or allogeneic stem cell transplantation
  • Zubrod performance status 0 to 2
  • No clinical evidence of leptomeningeal disease 
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org